Establishment and characterization of a novel cell line derived from human thymoma AB tumor

Yesim Gökmen-Polar, Kerry L. Sanders, Chirayu P. Goswami, Oscar D. Cano, Narjis A. Zaheer, Rohit K. Jain, Kenneth A. Kesler, Robert P. Nelson, Gail H. Vance, Danielle Smith, Lang Li, Angelo A. Cardoso, Sunil Badve, Patrick J. Loehrer, George W. Sledge

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Thymomas are low-grade epithelial tumors of the anterior mediastinum. The complexity of the disease and the lack of in vitro and in vivo models hamper the development of better therapeutics. In this study, we report a novel cell line, designated as IU-TAB-1, which was established from a patient with stage II thymoma (World Health Organization-type AB). The IU-TAB-1 cell line was established in vitro and characterized using histological and immunohistochemical staining, fluorescence-activated cell sorting, cytogenetic analyses and functional assays including in vitro and a NOD/SCID xenograft model. A whole-genome gene expression analysis (Illumina) was performed on the IU-TAB-1 cell line and 34 thymomas to determine the clinical relevance of the cell line. The IU-TAB-1 cell line was positive for epithelial markers (pan-cytokeratin and EpCAM/CD326) including thymic epithelial (TE) surface markers (such as CD29, CD9, CD54/ICAM-1, CD58 and CD24) and p63, and negative for B-and T-cell lineage markers. Gene expression profiling demonstrated overlapping and distinct genes between IU-TAB-1 and primary thymomas including the primary tumor (from which the cell line was derived). IU-TAB-1 cells are tumorigenic when implanted in immunodeficient mice with tumors reaching a volume of 1000 mm 3 at around 130 days. The established cell line represents a biologically relevant new tool to investigate the molecular pathology of thymic malignancies and to evaluate the efficacy of novel therapeutics both in vitro and in vivo.

Original languageEnglish (US)
Pages (from-to)1564-1573
Number of pages10
JournalLaboratory Investigation
Volume92
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Thymoma
Cell Line
Neoplasms
Overlapping Genes
Molecular Pathology
Cytogenetic Analysis
Mediastinum
Gene Expression Profiling
Cell Lineage
Intercellular Adhesion Molecule-1
Keratins
Tumor Cell Line
Heterografts
Flow Cytometry
Genome
Staining and Labeling
T-Lymphocytes
Gene Expression
In Vitro Techniques
Therapeutics

Keywords

  • gene expression analysis
  • human epithelial cancer cell lines
  • thymoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

Gökmen-Polar, Y., Sanders, K. L., Goswami, C. P., Cano, O. D., Zaheer, N. A., Jain, R. K., ... Sledge, G. W. (2012). Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Laboratory Investigation, 92(11), 1564-1573. https://doi.org/10.1038/labinvest.2012.115

Establishment and characterization of a novel cell line derived from human thymoma AB tumor. / Gökmen-Polar, Yesim; Sanders, Kerry L.; Goswami, Chirayu P.; Cano, Oscar D.; Zaheer, Narjis A.; Jain, Rohit K.; Kesler, Kenneth A.; Nelson, Robert P.; Vance, Gail H.; Smith, Danielle; Li, Lang; Cardoso, Angelo A.; Badve, Sunil; Loehrer, Patrick J.; Sledge, George W.

In: Laboratory Investigation, Vol. 92, No. 11, 01.11.2012, p. 1564-1573.

Research output: Contribution to journalArticle

Gökmen-Polar, Yesim ; Sanders, Kerry L. ; Goswami, Chirayu P. ; Cano, Oscar D. ; Zaheer, Narjis A. ; Jain, Rohit K. ; Kesler, Kenneth A. ; Nelson, Robert P. ; Vance, Gail H. ; Smith, Danielle ; Li, Lang ; Cardoso, Angelo A. ; Badve, Sunil ; Loehrer, Patrick J. ; Sledge, George W. / Establishment and characterization of a novel cell line derived from human thymoma AB tumor. In: Laboratory Investigation. 2012 ; Vol. 92, No. 11. pp. 1564-1573.
@article{2f5270681b19493fa64448173d37bc07,
title = "Establishment and characterization of a novel cell line derived from human thymoma AB tumor",
abstract = "Thymomas are low-grade epithelial tumors of the anterior mediastinum. The complexity of the disease and the lack of in vitro and in vivo models hamper the development of better therapeutics. In this study, we report a novel cell line, designated as IU-TAB-1, which was established from a patient with stage II thymoma (World Health Organization-type AB). The IU-TAB-1 cell line was established in vitro and characterized using histological and immunohistochemical staining, fluorescence-activated cell sorting, cytogenetic analyses and functional assays including in vitro and a NOD/SCID xenograft model. A whole-genome gene expression analysis (Illumina) was performed on the IU-TAB-1 cell line and 34 thymomas to determine the clinical relevance of the cell line. The IU-TAB-1 cell line was positive for epithelial markers (pan-cytokeratin and EpCAM/CD326) including thymic epithelial (TE) surface markers (such as CD29, CD9, CD54/ICAM-1, CD58 and CD24) and p63, and negative for B-and T-cell lineage markers. Gene expression profiling demonstrated overlapping and distinct genes between IU-TAB-1 and primary thymomas including the primary tumor (from which the cell line was derived). IU-TAB-1 cells are tumorigenic when implanted in immunodeficient mice with tumors reaching a volume of 1000 mm 3 at around 130 days. The established cell line represents a biologically relevant new tool to investigate the molecular pathology of thymic malignancies and to evaluate the efficacy of novel therapeutics both in vitro and in vivo.",
keywords = "gene expression analysis, human epithelial cancer cell lines, thymoma",
author = "Yesim G{\"o}kmen-Polar and Sanders, {Kerry L.} and Goswami, {Chirayu P.} and Cano, {Oscar D.} and Zaheer, {Narjis A.} and Jain, {Rohit K.} and Kesler, {Kenneth A.} and Nelson, {Robert P.} and Vance, {Gail H.} and Danielle Smith and Lang Li and Cardoso, {Angelo A.} and Sunil Badve and Loehrer, {Patrick J.} and Sledge, {George W.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1038/labinvest.2012.115",
language = "English (US)",
volume = "92",
pages = "1564--1573",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Establishment and characterization of a novel cell line derived from human thymoma AB tumor

AU - Gökmen-Polar, Yesim

AU - Sanders, Kerry L.

AU - Goswami, Chirayu P.

AU - Cano, Oscar D.

AU - Zaheer, Narjis A.

AU - Jain, Rohit K.

AU - Kesler, Kenneth A.

AU - Nelson, Robert P.

AU - Vance, Gail H.

AU - Smith, Danielle

AU - Li, Lang

AU - Cardoso, Angelo A.

AU - Badve, Sunil

AU - Loehrer, Patrick J.

AU - Sledge, George W.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Thymomas are low-grade epithelial tumors of the anterior mediastinum. The complexity of the disease and the lack of in vitro and in vivo models hamper the development of better therapeutics. In this study, we report a novel cell line, designated as IU-TAB-1, which was established from a patient with stage II thymoma (World Health Organization-type AB). The IU-TAB-1 cell line was established in vitro and characterized using histological and immunohistochemical staining, fluorescence-activated cell sorting, cytogenetic analyses and functional assays including in vitro and a NOD/SCID xenograft model. A whole-genome gene expression analysis (Illumina) was performed on the IU-TAB-1 cell line and 34 thymomas to determine the clinical relevance of the cell line. The IU-TAB-1 cell line was positive for epithelial markers (pan-cytokeratin and EpCAM/CD326) including thymic epithelial (TE) surface markers (such as CD29, CD9, CD54/ICAM-1, CD58 and CD24) and p63, and negative for B-and T-cell lineage markers. Gene expression profiling demonstrated overlapping and distinct genes between IU-TAB-1 and primary thymomas including the primary tumor (from which the cell line was derived). IU-TAB-1 cells are tumorigenic when implanted in immunodeficient mice with tumors reaching a volume of 1000 mm 3 at around 130 days. The established cell line represents a biologically relevant new tool to investigate the molecular pathology of thymic malignancies and to evaluate the efficacy of novel therapeutics both in vitro and in vivo.

AB - Thymomas are low-grade epithelial tumors of the anterior mediastinum. The complexity of the disease and the lack of in vitro and in vivo models hamper the development of better therapeutics. In this study, we report a novel cell line, designated as IU-TAB-1, which was established from a patient with stage II thymoma (World Health Organization-type AB). The IU-TAB-1 cell line was established in vitro and characterized using histological and immunohistochemical staining, fluorescence-activated cell sorting, cytogenetic analyses and functional assays including in vitro and a NOD/SCID xenograft model. A whole-genome gene expression analysis (Illumina) was performed on the IU-TAB-1 cell line and 34 thymomas to determine the clinical relevance of the cell line. The IU-TAB-1 cell line was positive for epithelial markers (pan-cytokeratin and EpCAM/CD326) including thymic epithelial (TE) surface markers (such as CD29, CD9, CD54/ICAM-1, CD58 and CD24) and p63, and negative for B-and T-cell lineage markers. Gene expression profiling demonstrated overlapping and distinct genes between IU-TAB-1 and primary thymomas including the primary tumor (from which the cell line was derived). IU-TAB-1 cells are tumorigenic when implanted in immunodeficient mice with tumors reaching a volume of 1000 mm 3 at around 130 days. The established cell line represents a biologically relevant new tool to investigate the molecular pathology of thymic malignancies and to evaluate the efficacy of novel therapeutics both in vitro and in vivo.

KW - gene expression analysis

KW - human epithelial cancer cell lines

KW - thymoma

UR - http://www.scopus.com/inward/record.url?scp=84868568119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868568119&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2012.115

DO - 10.1038/labinvest.2012.115

M3 - Article

C2 - 22926645

AN - SCOPUS:84868568119

VL - 92

SP - 1564

EP - 1573

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 11

ER -